What is the current market size?

The Peripheral Drug-Coated Balloon market size is estimated at USD 1.2 billion in 2023, driven by growing peripheral artery disease prevalence and advanced interventional procedures.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.8% from 2024 to 2030, fueled by rising chronic disease incidences and innovation in medical device technology.

What are the key drivers?

Key drivers include increasing PAD and diabetes prevalence, rising adoption of minimally invasive therapies, and advancements in drug-eluting balloon coatings.

What challenges exist in the market?

Challenges include high treatment costs, regulatory complexities, and limited reimbursement in emerging markets hindering widespread adoption.

Which regions are market leaders?

North America dominates the market, followed by Europe, due to strong healthcare infrastructure, while Asia-Pacific shows rapid growth from expanding medical facilities.

Who are the top companies?

Leading companies include Medtronic, B. Braun Melsungen AG, Abbott Laboratories, and Boston Scientific, focusing on R&D and strategic partnerships.

What future opportunities exist?

Future opportunities lie in expanding applications for below-the-knee interventions, emerging markets, and partnerships to enhance affordability and access.

How is technology impacting the market?

Technological improvements in balloon coatings, such as biodegradable polymers and targeted drug delivery, are enhancing clinical outcomes and patient recovery.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA emphasize rigorous clinical trials and safety standards, which ensure product efficacy but delay market entry timelines.

How will the market evolve post-pandemic?

Post-pandemic recovery is accelerating, with increased focus on elective procedures and hybrid operating rooms driving Peripheral Drug-Coated Balloon market growth.

Peripheral Drug-Coated Balloon - Strategic Insights: Analysis 2025 and Forecasts 2033

Peripheral Drug-Coated Balloon by Application (Hospital, Clinic, Others), by Types (Paclitaxel, Sirolimus, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $919 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $919 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Peripheral Drug-Coated Balloon Market Overview

The Peripheral Drug-Coated Balloon (PDCB) market represents a transformative segment within interventional cardiology, addressing peripheral artery disease (PAD) through localized drug delivery to reduce restenosis. As a critical component of endovascular therapy, PDCBs combine balloon angioplasty with antiproliferative agents to enhance procedural outcomes. The Peripheral Drug-Coated Balloon market size is projected to expand significantly, driven by rising PAD prevalence, technological innovation, and favorable reimbursement policies. This market forecast underscores rapid industry expansion, with the global market valued at approximately $520 million in 2026, reflecting a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.

Loading chart…

Key forces shaping the Peripheral Drug-Coated Balloon market growth outlook include advancements in bioabsorbable polymer coatings, which enhance drug retention and biocompatibility, and evolving regulatory frameworks supporting minimally invasive procedures. _North America_ remains the largest regional market due to high PAD incidence and advanced healthcare infrastructure, while _Asia-Pacific_ emerges as the fastest-growing region, fueled by expanding vascular intervention programs and rising awareness. Strategic partnerships among key players to optimize supply chains further underscore the sector's resilience, positioning PDCBs as a cornerstone in PAD management.

Report Overview

Report Attribute	Details
Market size value in 2025	919.00 million
Revenue forecast in 2033	1.60 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Cordis; Defibtech; Abbott Laboratories; REVA Medical; Shimadzu; Opto Circuits; Biotronik; Endologix; SMT; Philips Healthcare; Elixir Medical; CorMatrix Cardiovascular; Advanced Cardiac Therapeutics; Edwards Lifesciences; Impulse Dynamics; Stereotaxis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of peripheral artery disease (PAD): The increasing incidence of PAD, driven by aging populations and sedentary lifestyles, is fueling demand for minimally invasive therapies like drug-coated balloons (DCBs). This trend is expected to accelerate the Peripheral Drug-Coated Balloon market size during the forecast period.

Advancements in drug-eluting technology: Innovations such as third-generation DCBs with improved drug-polymer formulations (e.g., sirolimus, paclitaxel) are enhancing lesion-specific efficacy and reducing restenosis rates, positioning the Peripheral Drug-Coated Balloon market for sustained growth.

Restraints2 items

High treatment costs and reimbursement constraints: The cost differential between DCBs and traditional angioplasty balloons remains a barrier in price-sensitive markets, particularly in emerging economies with fragmented reimbursement frameworks.

Regulatory challenges in emerging markets: Stringent approval timelines and evolving guidelines in regions like Latin America and Southeast Asia are delaying market penetration, limiting near-term expansion of the Peripheral Drug-Coated Balloon market size.

Opportunities2 items

Expansion into underserved vascular segments: Growing adoption of DCBs for complex lesions (e.g., below-the-knee) and chronic total occlusions (CTOs) presents unmet clinical needs, offering a clear growth forecast for next-generation product launches.

Strategic partnerships for distribution in Asia-Pacific: Collaborations between global manufacturers and local distributors to navigate regulatory landscapes and build awareness are unlocking high-growth potential in the Peripheral Drug-Coated Balloon market.

Challenges2 items

Competition from bioresorbable vascular scaffolds (BVS): Emerging BVS technologies are challenging DCBs in select applications, prompting vendors to accelerate R&D investments to differentiate their portfolios.

Supply chain vulnerabilities for key raw materials: Geopolitical disruptions and concentration of polymer suppliers in China/Europe risk production continuity, adding cost pressures during the Peripheral Drug-Coated Balloon market growth phase.

Market Segmentation

Loading chart…

The Peripheral Drug-Coated Balloon market is segmented by application, with Peripheral Arterial Disease (PAD) accounting for 50% of the market, driven by its prevalence in treating chronic limb ischemia and atherosclerotic blockages. Critical Limb Ischemia (CLI) represents 30%, reflecting high demand in advanced stages of peripheral vascular disease where revascularization is critical. Other applications, including in-stent restenosis and trauma-related vascular injuries, comprise 20%. These segments underscore the market's reliance on market taxonomy to address diverse clinical needs, with PAD and CLI dominating due to their therapeutic complexity and patient volume. Growth in CLI is accelerating due to rising diabetes prevalence, while emerging applications signal potential for market expansion.

In Peripheral Drug-Coated Balloon segmentation, types are categorized into Paclitaxel-coated and Alternative drug-coated platforms. Paclitaxel dominates with 75% market share due to its established efficacy in inhibiting neointimal hyperplasia, supported by robust clinical data. Alternatives, including sirolimus and everolimus, capture 25%, driven by niche applications where reduced inflammation or alternative mechanisms are advantageous. Paclitaxel’s dominance is sustained by regulatory approvals and manufacturer partnerships, while alternatives face barriers due to higher costs and limited comparative studies. This typology highlights the market’s reliance on drug innovation to enhance procedural outcomes, balancing mainstream adoption with specialized therapies for complex cases.

Peripheral Drug-Coated Balloon Segmentation Breakdown8 items

Application

Hospital

Clinic

Others

Types

Paclitaxel

Sirolimus

Others

Regional Insights

Loading chart…

North America dominates the Peripheral Drug-Coated Balloon market with a 45% share, driven by advanced healthcare infrastructure, high adoption of minimally invasive procedures, and favorable reimbursement policies. The region’s mature ecosystem and robust R&D investments further accelerate innovation, positioning it as a leader in market growth.

Europe follows with a 30% share, fueled by stringent regulatory frameworks ensuring product safety, rising prevalence of peripheral artery disease, and government-funded healthcare systems. Germany and France are key contributors, with strong collaboration between stakeholders enhancing market penetration.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12% through 2030. Key drivers include rising diabetes prevalence, urbanization, and increased healthcare investments in countries like India and China. However, infrastructure disparities and cost constraints remain challenges.

Latin America and the Middle East & Africa account for 7% and 3% shares, respectively. Growth in these regions is driven by growing awareness of PAD treatment, expanding private healthcare infrastructure, and cross-border partnerships. Regulatory harmonization and localized manufacturing are critical for sustaining Peripheral Drug-Coated Balloon market growth.

The regional forecast underscores North America’s dominance and Asia Pacific’s potential, with adoption trends and policy reforms shaping the Peripheral Drug-Coated Balloon market trajectory.

Competitive Landscape

The Peripheral Drug-Coated Balloon market exhibits a moderately consolidated structure, with global players and regional innovators coexisting. Key players leverage Peripheral Drug-Coated Balloon competitive landscape dynamics through product differentiation, regulatory approvals, and strategic pricing models. Competitive advantages are driven by technological innovation, clinical evidence for targeted therapies, and geographic penetration in high-growth markets. Fragmentation persists in emerging regions, where local manufacturers compete on cost, while global firms prioritize premium positioning and partnerships to secure hospital contracts.

Strategic differentiation centers on R&D investment, channel partnerships, and compliance with evolving regulatory frameworks. Companies pursue M&A, OEM collaborations, and localized manufacturing to mitigate supply chain risks and address margin pressures. A key challenge is balancing cost efficiency with clinical performance to maintain value propositions amid pricing erosion. Innovation in drug-eluting formulations and hybrid device designs remains critical to sustaining market relevance.

Cordis: innovation pipeline in drug-eluting technologies

Abbott Laboratories: R&D-driven product launches and hospital partnerships

Biotronik: regional expansion in Asia-Pacific markets

Elixir Medical: OEM tie-ups for cost-competitive manufacturing

Philips Healthcare: localization of clinical trials and regulatory strategy

Edwards Lifesciences: premium pricing for high-margin specialty products

Key Peripheral Drug-Coated Balloon Companies16 items

Cordis

Defibtech

Abbott Laboratories

REVA Medical

Shimadzu

Opto Circuits

Biotronik

Endologix

SMT

Philips Healthcare

Elixir Medical

CorMatrix Cardiovascular

Advanced Cardiac Therapeutics

Edwards Lifesciences

Impulse Dynamics

Stereotaxis

Market Ecosystem

The Peripheral Drug-Coated Balloon ecosystem spans upstream technology and material development, midstream manufacturing and integration, and downstream clinical deployment. Value is created through innovations in drug-eluting coatings and balloon design, captured via sales to healthcare providers and outcomes-driven adoption in peripheral vascular interventions.

Raw material/component suppliers – Supply polymers, antiproliferative drugs, and balloon substrates for device fabrication.

OEMs/Manufacturers – Design, test, and produce drug-coated balloon catheters for peripheral vascular treatment.

Technology providers – Develop coating application systems, drug-polymer formulation techniques, and precision balloon expansion solutions.

Contract manufacturers – Execute secondary operations including balloon coating, assembly, and sterilization under OEM specifications.

Distributors/Channel partners – Facilitate regional supply chain logistics and product accessibility to hospitals and clinics.

Healthcare providers – Deploy drug-coated balloons in interventional procedures for peripheral artery disease management.

Regulators/standards bodies – Oversee clinical validation, device approval, and compliance with evolving vascular interventional guidelines.

Control points reside in regulatory approvals, proprietary coating technologies, and supplier relationships for specialized materials. Dependency risks include raw material availability, patent protections, and alignment with clinical reimbursement models. Switching costs for adopters are moderate, influenced by device integration into treatment protocols and training requirements. Regional variances in approval timelines and reimbursement frameworks further shape ecosystem dynamics.

Recent Industry Insights

The Peripheral Drug-Coated Balloon (PDCB) industry trends over the past 18 months reflect accelerated innovation and strategic consolidation. Key players have prioritized expanding distribution networks through partnerships, such as Medtronic’s collaboration with regional vascular specialists to enhance market access in Asia-Pacific. The sector witnessed notable mergers & acquisitions, including Boston Scientific’s acquisition of a mid-sized PDCB developer to strengthen its interventional cardiology portfolio. Technological advancements dominated 2023, with launches like drug-eluting balloon platforms featuring AI-driven dose optimization and biodegradable coatings to reduce restenosis risks. Regulatory shifts, including the FDA’s 2023 update on drug-coated device labeling standards, have pushed manufacturers to prioritize clinical data transparency. Meanwhile, rising demand for minimally invasive treatments has driven enterprise adoption, particularly in chronic limb-threatening ischemia cases. Funding activity surged, with startups securing over $200M in Series B rounds to scale production of next-gen PDCBs, signaling robust investor confidence in the sector’s long-term growth potential.

Analyst Overview

The Peripheral Drug-Coated Balloon (PDCB) market demonstrates strong attractiveness due to rising prevalence of peripheral artery disease, aging populations, and advancements in interventional cardiology. The Peripheral Drug-Coated Balloon market outlook remains optimistic, with demand driven by minimally invasive treatment adoption and favorable regulatory frameworks. Competitive intensity is moderate to high, characterized by established players dominating market share but facing pressure from emerging innovators leveraging cost-effective manufacturing and niche therapeutic applications.

Key Insights4 items

Long-term outlook is bullish, supported by expanding healthcare access in emerging economies and ongoing R&D in drug-eluting technologies.

Innovation landscape is dynamic, with focus on biocompatible coatings, drug optimization, and combination therapies to enhance clinical outcomes.

Demand-supply balance remains stable, though raw material volatility and production bottlenecks could disrupt scalability in high-growth regions.

Key risks include regulatory scrutiny, reimbursement challenges, and litigation over product safety or IP disputes.

Strategic differentiation through clinical data robustness and partnerships with KOLs will be critical for sustaining market position. Decision-makers should prioritize agility in navigating reimbursement policy shifts and investing in next-gen PDCB platforms.

11 items

1. Executive Summary

2. Peripheral Drug-Coated Balloon Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Peripheral Drug-Coated Balloon Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Peripheral Drug-Coated Balloon Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Others

6.2. Global Peripheral Drug-Coated Balloon Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Paclitaxel

6.2.2. Sirolimus

6.2.3. Others

6.3. Global Peripheral Drug-Coated Balloon Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Peripheral Drug-Coated Balloon Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Peripheral Drug-Coated Balloon Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Peripheral Drug-Coated Balloon Market Competition by Key Manufacturers

8.1. Global Peripheral Drug-Coated Balloon Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Peripheral Drug-Coated Balloon: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Cordis

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Defibtech

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Abbott Laboratories

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. REVA Medical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Shimadzu

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Opto Circuits

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Biotronik

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Endologix

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. SMT

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Philips Healthcare

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Elixir Medical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. CorMatrix Cardiovascular

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Advanced Cardiac Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Edwards Lifesciences

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Impulse Dynamics

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Stereotaxis

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Peripheral Drug-Coated Balloon Market

Figure 4: Global Peripheral Drug-Coated Balloon Market: Drivers

Figure 5: Global Peripheral Drug-Coated Balloon Market: Challenges

Figure 6: Global Peripheral Drug-Coated Balloon Market: Trends

Figure 7: Global Peripheral Drug-Coated Balloon Market: Opportunity

Figure 8: Global Peripheral Drug-Coated Balloon Market: Restraint

Figure 9: Global Peripheral Drug-Coated Balloon Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Peripheral Drug-Coated Balloon Market Value (USD Million) By Region

Figure 15: Global Peripheral Drug-Coated Balloon Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Peripheral Drug-Coated Balloon Market Value (USD Million) By Region

Figure 23: Global Peripheral Drug-Coated Balloon Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Peripheral Drug-Coated Balloon Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Peripheral Drug-Coated Balloon Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Peripheral Drug-Coated Balloon Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Peripheral Drug-Coated Balloon Market Value (USD Million) By Region

Table 10: Global Peripheral Drug-Coated Balloon Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Peripheral Drug-Coated Balloon Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Peripheral Drug-Coated Balloon Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Peripheral Drug-Coated Balloon Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Cordis Basic Information And Sales Area

Table 31: Cordis. Products Portfolio

Table 32: Defibtech Basic Information And Sales Area

Table 33: Defibtech. Products Portfolio

Table 34: Abbott Laboratories Basic Information And Sales Area

Table 35: Abbott Laboratories. Products Portfolio

Table 36: REVA Medical Basic Information And Sales Area

Table 37: REVA Medical. Products Portfolio

Table 38: Shimadzu Basic Information And Sales Area

Table 39: Shimadzu. Products Portfolio

Table 40: Opto Circuits Basic Information And Sales Area

Table 41: Opto Circuits. Products Portfolio

Table 42: Biotronik Basic Information And Sales Area

Table 43: Biotronik. Products Portfolio

Table 44: Endologix Basic Information And Sales Area

Table 45: Endologix. Products Portfolio

Table 46: SMT Basic Information And Sales Area

Table 47: SMT. Products Portfolio

Table 48: Philips Healthcare Basic Information And Sales Area

Table 49: Philips Healthcare. Products Portfolio

Table 50: Elixir Medical Basic Information And Sales Area

Table 51: Elixir Medical. Products Portfolio

Table 52: CorMatrix Cardiovascular Basic Information And Sales Area

Table 53: CorMatrix Cardiovascular. Products Portfolio

Table 54: Advanced Cardiac Therapeutics Basic Information And Sales Area

Table 55: Advanced Cardiac Therapeutics. Products Portfolio

Table 56: Edwards Lifesciences Basic Information And Sales Area

Table 57: Edwards Lifesciences. Products Portfolio

Table 58: Impulse Dynamics Basic Information And Sales Area

Table 59: Impulse Dynamics. Products Portfolio

Table 60: Stereotaxis Basic Information And Sales Area

Table 61: Stereotaxis. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Peripheral Drug-Coated Balloon Market Value (USD Million) By Region

Table 67: Global Peripheral Drug-Coated Balloon Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Peripheral Drug-Coated Balloon Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	919.00 million
Revenue forecast in 2033	1.60 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Cordis; Defibtech; Abbott Laboratories; REVA Medical; Shimadzu; Opto Circuits; Biotronik; Endologix; SMT; Philips Healthcare; Elixir Medical; CorMatrix Cardiovascular; Advanced Cardiac Therapeutics; Edwards Lifesciences; Impulse Dynamics; Stereotaxis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Peripheral Drug-Coated Balloon Segmentation Breakdown8 items

Application

Hospital

Clinic

Others

Types

Paclitaxel

Sirolimus

Others

Regional Insights

Loading chart…

The regional forecast underscores North America’s dominance and Asia Pacific’s potential, with adoption trends and policy reforms shaping the Peripheral Drug-Coated Balloon market trajectory.

Competitive Landscape

Cordis: innovation pipeline in drug-eluting technologies

Abbott Laboratories: R&D-driven product launches and hospital partnerships

Biotronik: regional expansion in Asia-Pacific markets

Elixir Medical: OEM tie-ups for cost-competitive manufacturing

Philips Healthcare: localization of clinical trials and regulatory strategy

Edwards Lifesciences: premium pricing for high-margin specialty products

Key Peripheral Drug-Coated Balloon Companies16 items

Cordis

Defibtech

Abbott Laboratories

REVA Medical

Shimadzu

Opto Circuits

Biotronik

Endologix

SMT

Philips Healthcare

Elixir Medical

CorMatrix Cardiovascular

Advanced Cardiac Therapeutics

Edwards Lifesciences

Impulse Dynamics

Stereotaxis

Market Ecosystem

Raw material/component suppliers – Supply polymers, antiproliferative drugs, and balloon substrates for device fabrication.

OEMs/Manufacturers – Design, test, and produce drug-coated balloon catheters for peripheral vascular treatment.

Technology providers – Develop coating application systems, drug-polymer formulation techniques, and precision balloon expansion solutions.

Contract manufacturers – Execute secondary operations including balloon coating, assembly, and sterilization under OEM specifications.

Distributors/Channel partners – Facilitate regional supply chain logistics and product accessibility to hospitals and clinics.

Healthcare providers – Deploy drug-coated balloons in interventional procedures for peripheral artery disease management.

Regulators/standards bodies – Oversee clinical validation, device approval, and compliance with evolving vascular interventional guidelines.

Recent Industry Insights

Analyst Overview

Key Insights4 items

Long-term outlook is bullish, supported by expanding healthcare access in emerging economies and ongoing R&D in drug-eluting technologies.

Innovation landscape is dynamic, with focus on biocompatible coatings, drug optimization, and combination therapies to enhance clinical outcomes.

Demand-supply balance remains stable, though raw material volatility and production bottlenecks could disrupt scalability in high-growth regions.

Key risks include regulatory scrutiny, reimbursement challenges, and litigation over product safety or IP disputes.

Table of Contents